Fluocinonide
NDC Package 45802-151-96

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Fluocinonide is a medication used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Marketed by Padagis Israel Pharmaceuticals Ltd, this product is identified by NDC 45802-151 and is authorized under FDA application ANDA090256.

Identification & Billing

NDC Package Code
45802-151-96
Package Description
1 TUBE in 1 CARTON / 60 g in 1 TUBE
Product Code
45802-151
11-Digit Billing Format
45802015196
Billing Unit
GM - Billing unit of "gram" is used when a product is measured by its weight.
Units Per Package
60 GM
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Fluocinonide
Dosage Form
-
Usage Information
This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Fluocinonide reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a strong corticosteroid.

Regulatory & Marketing

Labeler Name
Padagis Israel Pharmaceuticals Ltd
FDA Application #
ANDA090256
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-14-2014
End Marketing Date
03-31-2025
Listing Expiration
03-31-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (45802-151). Click a package code to view its specific billing and regulatory data.

45802-151-53
1 TUBE in 1 CARTON / 120 g in 1 TUBE
45802-151-94
1 TUBE in 1 CARTON / 30 g in 1 TUBE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 45802-151-96 identifies a specific commercial package of 1 tube in 1 carton / 60 g in 1 tube of Fluocinonide, labeled by Padagis Israel Pharmaceuticals Ltd. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Padagis Israel Pharmaceuticals Ltd on January 14, 2014. The current certification is valid through March 31, 2025.

What are the primary indications for this medication?

This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Fluocinonide reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a strong corticosteroid.

How is this Padagis Israel Pharmaceuticals Ltd product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 45802015196. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
45802-151-96
11-Digit CMS (5-4-2)
45802-0151-96

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.